Key result
Bivalirudin reduces major bleeding and all-cause mortality compared to heparin plus a glycoprotein IIb/IIIa inhibitor in STEMI, though acute stent thrombosis is a potential risk within 24 hours.
Why the study?
Does bivalirudin reduce major bleeding and mortality compared to heparin plus a glycoprotein IIb/IIIa inhibitor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention?
Does bivalirudin reduce major bleeding and mortality compared to heparin plus a glycoprotein IIb/IIIa inhibitor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention?
Bivalirudin reduces major bleeding and all-cause mortality compared to heparin plus a glycoprotein IIb/IIIa inhibitor in STEMI patients undergoing primary PCI, though it may increase the risk of acute stent thrombosis.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating in STEMI; should not change practice without randomized confirmation.
Kate O’Donovan (2015) conducted a review in ST-segment elevation myocardial infarction. Bivalirudin vs. Heparin plus a glycoprotein IIb/IIIa inhibitor was evaluated. Bivalirudin reduces major bleeding and all-cause mortality compared to heparin plus a glycoprotein IIb/IIIa inhibitor in STEMI, though acute stent thrombosis is a potential risk within 24 hours.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: